5:28 PM
 | 
Sep 13, 2012
 |  BC Extra  |  Clinical News

DUSA up on actinic keratosis data

DUSA Pharmaceuticals Inc. (NASDAQ:DUSA) gained $0.37 to $5.75 on Thursday after Levulan Kerastick followed by DUSA's Blue Light Photodynamic Therapy Illuminator (BLU-U) met the primary endpoint in a Phase II trial in 70 patients with minimally...

Read the full 166 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >